uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer

• Status: Unknown status
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Biopsy-verified urinary bladder cancer

• The participants must be capable of understanding and giving full informed written consent age above 18 years

Exclusion Criteria:

• Pregnancy

• Lactation/breast feeding

• Age above 85 years old

• Weight above 140 kg

• Treatment with neoadjuvant chemotherapy

• Known allergy towards 68Ga-NOTA-AE105

• Other malignant disease within last 5 years, except for non-melanoma